General Information
Drug ID
DR00382
Drug Name
Montelukast
Synonyms
(R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 1-((((1R)-1-(3-((1E)-2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid; 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid; Apxi toxin; Brondilat; Brondilat (TN); MK 0476; MK-0476; Montair; Montelukast (INN); Montelukast [INN:BAN]; Singulair (TN); Singular; Sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate; {1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid
Drug Type
Small molecular drug
Indication Asthma [ICD11: CA23] Approved [1]
Therapeutic Class
Antiasthmatic Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=5281040"></iframe>
3D MOL 2D MOL
Formula
C35H36ClNO3S
Canonical SMILES
CC(C)(C1=CC=CC=C1CCC(C2=CC=CC(=C2)C=CC3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O
InChI
InChI=1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1
InChIKey
UCHDWCPVSPXUMX-TZIWLTJVSA-N
CAS Number
CAS 158966-92-8
Pharmaceutical Properties Molecular Weight 586.187 Topological Polar Surface Area 95.7
Heavy Atom Count 41 Rotatable Bond Count 12
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 5
PubChem CID
5281040
PubChem SID
103207442 , 103948950 , 113854447 , 124899385 , 126681707 , 127278617 , 127278618 , 127278619 , 127278620 , 127278621 , 127278622 , 127278623 , 127278624 , 127278625 , 127278626 , 127278627 , 127278628 , 127278629 , 127278630 , 127278631 , 127278632 , 127278633 , 127278634 , 127278635 , 127278636 , 134337621 , 135039402 , 137156298 , 140071379 , 14886895 , 14886896 , 160963817 , 162011440 , 163669670 , 172440032 , 175268932 , 175612182 , 39289972 , 46505585 , 48416293 , 50064526 , 53786760 , 56352853 , 57357981 , 75937172 , 8616482 , 92308743 , 93166552 , 96024917 , 9685
ChEBI ID
ChEBI:50730
TTD Drug ID
D00QET
DT(s) Transporting This Drug OATP1A2 Transporter Info Organic anion transporting polypeptide 1A2 Substrate [2]
OATP2B1 Transporter Info Organic anion transporting polypeptide 2B1 Substrate [3]
References
1 Montelukast was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast. J Clin Pharmacol. 2011 May;51(5):751-60.
3 Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans. J Clin Pharmacol. 2013 Nov;53(11):1186-93.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.